Find us @

Feature

WHO is a grouping of scientists that tests and operates on new treatments for infectious diseases

The World Health Organization said Friday that they recommend two existing treatments and should be given to all people of all ages who suffer from haemorrhagic fever.

Published

on

The World Health Organization announced on Friday that two current medications have significantly decreased Ebola fatalities and should be administered to patients of all ages with the frequently fatal haemorrhagic disease.

The UN health agency strongly advised employing two monoclonal antibodies: mAb114, also known as Ansuvimab or Ebanga, and REGN-EB3, or Inmazeb, in its first-ever advice on which medicines to use against Ebola.

Janet Diaz, head of the clinical management unit in the WHO’s Health Emergencies programme, told reporters in Geneva that studies had revealed that the two therapies “substantially reduced mortality.”

She said that for every 1,000 afflicted persons, they may save between 230 and 400 lives, depending on the level of care.

The WHO advised against employing antiviral medication remdesivir and monoclonal antibody ZMapp, two treatments that have been evaluated for Ebola, in its recommendations.

The first case of the frequently lethal viral hemorrhagic fever known as Ebola was discovered in central Africa in 1976. The disease was given its name after a river in what was then known as Zaire, the Democratic Republic of the Congo.

Between 2013 and 2016, the biggest outbreak to hit West Africa claimed the lives of over 11,300 people. More than a dozen epidemics have occurred in the DRC, with the largest killing 2,280 people in 2020.

Depending on how quickly it is identified and treated, the disease’s case fatality rate, which involves a high fever, vomiting, and bleeding, can range from 80 to 90 percent.

Anyone who catches the virus should receive mAb114 and REGN-EB3 right away, according to the WHO.

The health service claimed in a statement that the two had “demonstrated clear benefits” and could be used on all Ebola patients, including elderly adults, pregnant and nursing women, toddlers, and newborns.

It advised that neutralizing monoclonal antibodies be administered to patients as soon as feasible once a diagnosis has been confirmed by a laboratory.

According to the UN office for health, “WHO is ready to support countries, producers, and partners to enhance access to these therapies, as well as to support national and international initiatives to increase affordability.”

The guideline development group’s co-chair, Robert Fowler of the University of Toronto, applauded how “advances in supportive care and medications over the past decade have changed the treatment of Ebola.”

“The Ebola virus sickness was once thought to be almost guaranteed to kill. That is no longer the case, though “In the statement, he said.

The two suggested treatments “mean healing for the vast majority of people” when used in conjunction with appropriate care, he said.

nl/apo/rox/lcm